Tariquidar, also known as XR9576, is a P-glycoprotein (P-gp) inhibitor undergoing research as an adjuvant against multidrug resistance in cancer. Tariquidar non-competitively binds to the p-glycoprotein transporter, thereby inhibiting transmembrane transport of anticancer drugs. Inhibition of transmembrane transport may result in increased intracellular concentrations of an anticancer drug, thereby augmenting its cytotoxicity.
P-glycoprotein Related Products:
Elacridar; Glibenclamide; Zosuquidar trihydrochloride; Selamectin; Atazanavir; Des(benzylpyridyl) Atazanavir; Valspodar